Clinical trial comparing lidocaine 5% with fentanyl and Marcaine on the duration of spinal anesthesia in pregnant women

Comparative study of the duration of analgesia following spinal anesthesia with lidocaine 5% with fentanyl and marcain in pregnant women under cesarean section

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201707157745N9

Enrollment

200

Registered

2017-08-12

Start date

2017-02-03

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Spinal Anesthesia in pregnant patient. Condition 2: Spinal Anesthesia in pregnant patient. 094-099 094-099

Interventions

Intervention 1: Marcaine injected in the subarachnoid space in a single dose, 4 mg. Intervention 2: We use two drugs in this study. Lidocaine 5%: injection in the subarachnoid space as a single dose

Treatment - Drugs

Treatment - Other

Marcaine injected in the subarachnoid space in a single dose, 4 mg

We use two drugs in this study. Lidocaine 5%: injection in the subarachnoid space as a single dose of 75 mg Fentanyl: injection in the subarachnoid space as a single dose ,50 macro grams Marca

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Inclusion criteria: Pregnant patients who come to the operating room for non-emergency c/s. Exclusion criteria: patients with a history of diabetes, addiction, drugs are sedatives and psychoactive drugs.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
The duration of analgesia after spinal anesthesia with lidocaine 5% with fentanyl and Marcaine in pregnant women undergoing cesarean section. Timepoint: 5 minutes after completion of caesarean section, Back pain at the site of action. Method of measurement: Touch the place.	—

Secondary

Measure	Time frame
Satisfaction and a pleasant feeling by the mother. Timepoint: After the surgery and recovery time. Method of measurement: Ask the patient and see the clinical symptoms.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDR.Afshin Mansourian

YUMS

afshin.mansourian@yahoo.com+98 74 3322 0166

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026